| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥939.3B | ¥915.1B | +2.6% |
| Operating Income | ¥90.0B | ¥85.7B | +5.0% |
| Ordinary Income | ¥94.7B | ¥82.0B | +15.5% |
| Net Income | ¥63.5B | ¥51.2B | +24.1% |
| ROE | 6.8% | 5.9% | - |
FY2026 Q3 cumulative results (April-December 2025): Revenue 939.3B yen (YoY +2.6%), Operating Income 90.0B yen (YoY +5.0%), Ordinary Income 94.7B yen (YoY +15.5%), Net Income 63.5B yen (YoY +24.1%). The company demonstrates robust bottom-line growth with net income expanding at 24.1%, significantly outpacing the 2.6% revenue growth. Operating margin improved to 9.6% with gross margin maintained at a strong 54.2%. The substantial 15.5% growth in ordinary income was driven by foreign exchange gains of 6.8B yen in non-operating income. However, working capital efficiency deteriorated notably, with inventory turnover extending to 153 days and cash conversion cycle lengthening to 211 days, presenting material operational concerns despite strong profitability metrics.
Revenue growth of 2.6% to 939.3B yen was primarily driven by the VisionCare segment, which generated 871.3B yen in sales (up from 845.6B yen YoY, +3.0%). The Other segment (Healthcare and Lifecare businesses) recorded 68.0B yen, slightly declining from 69.5B yen (-2.1%). Foreign exchange tailwinds contributed to top-line expansion, as evidenced by the 56.5B yen foreign currency translation adjustment in comprehensive income. The gross profit margin of 54.2% remained stable, with gross profit reaching 508.7B yen against cost of sales of 430.6B yen.
On the profit side, operating income increased 5.0% to 90.0B yen, outpacing revenue growth due to operational leverage. The SG&A expense ratio of 44.6% (418.7B yen) reflects continued investment in distribution and administrative functions, though improved efficiency is evident from the operating margin expansion to 9.6% from approximately 9.4% YoY. Ordinary income growth of 15.5% to 94.7B yen significantly exceeded operating income growth, primarily attributable to non-operating factors including foreign exchange gains of 6.8B yen, interest income of 1.1B yen, and dividend income of 0.3B yen. These gains more than offset interest expense of 6.1B yen related to bonds payable (450.0B yen) and long-term loans (173.5B yen).
The substantial 24.1% increase in net income to 63.5B yen reflects not only the ordinary income improvement but also stable tax management with an effective tax rate of approximately 32.6% (income tax expense 30.8B yen on profit before tax of 94.3B yen). No material extraordinary items impacted results, with extraordinary income of 0.2B yen and losses of 0.6B yen representing negligible factors. The profit progression demonstrates a revenue up/profit up pattern, with accelerating profit growth driven by operational efficiency gains and favorable foreign exchange effects.
The VisionCare segment serves as the core business, generating 871.3B yen in revenue (92.7% of total) with operating income of 138.8B yen at a 15.9% margin. This segment demonstrated healthy growth of 3.0% YoY from 845.6B yen, with operating profit increasing from 136.9B yen, reflecting improved operational efficiency. The segment margin of 15.9% substantially exceeds the consolidated operating margin of 9.6%, highlighting its strong profit contribution.
The Other segment, encompassing Healthcare and Lifecare businesses, recorded 68.0B yen in revenue with an operating loss of 2.2B yen (negative margin). This compares to a 6.7B yen operating loss in the prior year, showing meaningful improvement in loss reduction. The segment remains subscale relative to VisionCare, contributing 7.2% of revenue.
Corporate expenses not allocated to segments totaled 46.6B yen (up from 44.5B yen YoY), representing general administrative costs. This reconciling item explains the difference between segment operating income of 136.6B yen (VisionCare 138.8B yen minus Other losses 2.2B yen) and consolidated operating income of 90.0B yen. The VisionCare segment's dominant position and strong margin profile underscore its role as the primary earnings driver, while Other segment loss reduction indicates progress toward profitability in adjacent businesses.
[Profitability] ROE of 6.8% positions below the industry median of 5.8%, representing a relative outperformance though remaining in the modest range for manufacturing. Operating margin of 9.6% improved from 9.4% YoY, aligning closely with the industry median of 8.9% and demonstrating competitive operational efficiency. Net profit margin of 6.8% exceeds the industry median of 6.5%, reflecting effective cost management and favorable non-operating contributions. [Cash Quality] Cash and deposits of 336.9B yen provide robust liquidity, covering short-term debt 1.15 times. However, working capital of 500.1B yen and inventory of 180.5B yen (finished goods) signal capital intensity concerns. Inventory turnover of 153 days significantly exceeds the industry median of 112 days, indicating material inefficiency. [Investment Efficiency] Total asset turnover of 0.484 falls below the industry median of 0.56, reflecting the asset-heavy nature of operations. Return on assets of 3.3% trails the industry median of 3.4%. Return on invested capital stands at 6.0%, aligning with the industry median of 6.0%. [Financial Health] Equity ratio of 48.5% remains well below the industry median of 63.8%, suggesting relatively higher financial leverage. Financial leverage of 2.06 exceeds the industry median of 1.53, consistent with the company's debt-funded investment posture including bonds payable of 450.0B yen. Current ratio of 270.9% substantially exceeds the industry median of 287%, confirming strong short-term solvency. Debt-to-equity ratio of 1.06 remains manageable, with net debt to EBITDA positioning favorably given interest coverage of 14.7 times.
Cash and deposits increased 60.3B yen YoY to 336.9B yen, reflecting accumulated earnings and balance sheet expansion. Operating profitability contributed to this cash build, with net income of 63.5B yen representing a primary source. However, working capital movements warrant attention, as inventories expanded 15.0B yen YoY to 180.5B yen, and total current assets increased 87.5B yen to 792.8B yen. Trade receivables of 151.5B yen increased from prior levels, further absorbing operating cash. On the liability side, trade payables of 69.7B yen provide modest supplier credit, with payables turnover of 59 days comparing favorably to the industry median of 56 days. The substantial working capital buildup—particularly in finished goods inventory—suggests cash generation quality may be impaired relative to reported earnings. Short-term borrowings increased materially to 18.5B yen from 0.3B yen, potentially reflecting tactical liquidity management or seasonal working capital financing needs. Total assets expanded to 1,939.1B yen from 1,875.9B yen, with non-current assets of 1,146.3B yen (including property, plant and equipment of 934.2B yen) representing significant capital intensity. The equity base strengthened to 940.4B yen from 861.3B yen, supported by retained earnings growth and comprehensive income including 56.5B yen in foreign currency translation gains. Cash coverage of short-term liabilities stands at robust levels, though the efficiency of cash deployment in working capital presents optimization opportunities.
Ordinary income of 94.7B yen versus operating income of 90.0B yen reflects net non-operating contribution of approximately 4.7B yen. This comprises primarily foreign exchange gains of 6.8B yen, partially offset by interest expense of 6.1B yen. Non-operating income totaled 11.8B yen (1.3% of revenue), consisting of interest income 1.1B yen, dividend income 0.3B yen, FX gains 6.8B yen, and other non-operating income 2.9B yen. The significant FX gain component introduces variability and represents non-recurring enhancement to core operations. Extraordinary items were immaterial at 0.2B yen income and 0.6B yen losses, with no impairment charges reported. The earnings stream demonstrates solid core operating quality, though non-operating enhancements—particularly FX gains—merit adjustment in normalized earnings assessment. The divergence between operating income growth of 5.0% and ordinary income growth of 15.5% quantifies this non-operating amplification effect. While comprehensive income of 121.9B yen substantially exceeds net income due to 56.5B yen in translation adjustments, this reflects balance sheet translation effects rather than realized cash earnings. The absence of operating cash flow disclosure limits full accruals assessment, though the significant inventory buildup (153-day turnover versus 112-day industry median) suggests potential earnings quality pressure if inventory requires future valuation adjustments or clearance actions. Interest coverage of 14.7 times confirms strong earnings adequacy for debt service.
Full-year guidance projects revenue of 1,250.0B yen (YoY +2.9%), operating income of 102.0B yen (YoY +1.9%), ordinary income of 95.0B yen (YoY -0.7%), and net income of 58.0B yen. Q3 cumulative progress rates stand at 75.1% for revenue, 88.2% for operating income, 99.7% for ordinary income, and 109.5% for net income against full-year targets. Operating income and ordinary income are tracking well ahead of the 75% standard nine-month pace, indicating strong first nine-month execution. Net income progress of 109.5% has already exceeded the full-year target, suggesting potential for upward guidance revision or conservative initial forecasting. The revenue progress rate of 75.1% aligns with expectations, implying Q4 revenue of approximately 310.7B yen to achieve the 1,250.0B yen target. However, the guidance for ordinary income to decline 0.7% YoY to 95.0B yen appears inconsistent with Q3 cumulative performance of 94.7B yen (already near full-year target) and Q3 YoY growth of 15.5%, potentially reflecting anticipated reversal of FX gains or other non-operating factors in Q4. The operating income target of 102.0B yen implies Q4 operating income of 12.0B yen (versus Q3 cumulative 90.0B yen), suggesting seasonally modest fourth-quarter expectations. Given net income has exceeded full-year guidance through nine months, management's maintaining guidance may reflect conservatism or anticipated one-time factors in Q4.
Annual dividend forecast of 28.00 yen represents the full-year distribution, with no interim dividend paid. Based on forecasted full-year EPS of 77.56 yen, the implied payout ratio is 36.1%, which positions conservatively within sustainable ranges. Using actual nine-month EPS of 84.67 yen, the dividend represents a 33.1% payout ratio. The dividend policy reflects a moderate return of capital, maintaining substantial earnings retention for reinvestment. No share buyback activity is disclosed in the current period, with treasury stock increasing to book value of 31.1B yen from 9.3B yen, though specific repurchase amounts and timing are not detailed. The total return ratio remains equivalent to the payout ratio at approximately 36.1% in the absence of disclosed buybacks. Dividend coverage from net income appears adequate, though the sustainability should be assessed against free cash flow generation once disclosed. The conservative payout ratio provides flexibility for continued investment in working capital and capital expenditures while maintaining financial stability.
Working capital efficiency risk: Inventory turnover of 153 days and cash conversion cycle of 211 days significantly exceed industry norms (112 days median inventory turnover), indicating 15.0B yen YoY inventory accumulation. If demand weakens or product cycles shorten, inventory markdowns or obsolescence could pressure margins and require cash flow impairment of 8-12% of inventory value based on typical industry experience.
Foreign exchange volatility risk: The company recognized 6.8B yen in FX gains (7.2% of operating income) in non-operating income, with 56.5B yen in translation adjustments in comprehensive income. A reversal of yen weakness could eliminate this 7.2% boost to ordinary income and pressure consolidated equity through translation effects, with each 5% yen appreciation potentially impacting ordinary income by approximately 3-4B yen based on current exposure.
Segment concentration risk: VisionCare represents 92.7% of revenue and generates the entirety of segment profit (138.8B yen) while Other segments remain loss-making. Market share loss, pricing pressure from competitors, or regulatory changes in the vision care industry could materially impact consolidated results, with a 5% VisionCare revenue decline potentially reducing operating income by 25-30% given segment leverage.
[Industry Position - Manufacturing Sector] (Reference - Proprietary Analysis)
Profitability: ROE 6.8% (Industry Median 5.8%), Operating Margin 9.6% (Industry Median 8.9%), Net Profit Margin 6.8% (Industry Median 6.5%). Menicon demonstrates above-median profitability across key metrics, reflecting competitive pricing power and operational efficiency in the VisionCare segment.
Financial Health: Equity Ratio 48.5% (Industry Median 63.8%), Financial Leverage 2.06x (Industry Median 1.53x), Current Ratio 270.9% (Industry Median 287%). The equity ratio positions well below industry norms, indicating higher financial leverage through bonds and loans to fund capital-intensive manufacturing infrastructure. Current ratio remains robust and comparable to industry standards.
Efficiency: Asset Turnover 0.48x (Industry Median 0.56x), Inventory Turnover 153 days (Industry Median 112 days), Working Capital Turnover 211 days (Industry Median 112 days). Efficiency metrics reveal material underperformance, particularly in inventory management where Menicon's 153-day turnover exceeds the median by 37%, representing a structural working capital inefficiency requiring management attention.
Growth: Revenue Growth 2.6% (Industry Median 2.8%), EPS Growth 25.7%. Revenue growth aligns with industry pace, while EPS growth substantially exceeds typical performance due to operating leverage and non-operating gains.
Returns: Return on Assets 3.3% (Industry Median 3.4%), Return on Invested Capital 6.0% (Industry Median 6.0%). Return metrics align closely with industry benchmarks, though capital intensity and working capital absorption limit return on asset performance.
※ Industry: Manufacturing (105 companies), Comparison: FY2025 Q3 period, Source: Proprietary Analysis
Strong segment profitability with efficiency optimization opportunity: VisionCare segment margin of 15.9% demonstrates robust core business economics, substantially exceeding consolidated operating margin of 9.6%. The 871.3B yen segment scale and consistent growth trajectory position Menicon favorably in the vision care market. However, working capital metrics signal material inefficiency, with 153-day inventory turnover versus 112-day industry median representing opportunity for 15-20B yen cash release through inventory optimization. Management focus on demand planning and supply chain efficiency could unlock significant free cash flow improvement without revenue growth.
Bottom-line acceleration driven by operational leverage and FX tailwinds: Net income growth of 24.1% far exceeding revenue growth of 2.6% reflects operating leverage realization and 6.8B yen non-operating FX gains. The comprehensive income of 121.9B yen including 56.5B yen translation adjustments demonstrates substantial foreign operation scale. While FX benefits may prove transitory, the structural operating margin expansion from 9.4% to 9.6% with SG&A leverage indicates sustainable profit improvement trajectory as revenue scales.
Conservative capital allocation with balance sheet capacity: The 36.1% forecasted payout ratio and equity base expansion to 940.4B yen provide financial flexibility for strategic investment. However, the 48.5% equity ratio below 63.8% industry median and 450.0B yen in bonds payable indicate higher financial leverage. The 14.7x interest coverage and 336.9B yen cash position ensure debt service capacity, though optimizing the asset base efficiency—particularly 1,146.3B yen in non-current assets—could enhance return on invested capital beyond the current 6.0% industry-median level.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.